How to Value a Hospice Agency in 2026

Hospice is one of the most misunderstood and most valuable segments of healthcare services. Having spent years advising on healthcare M&A — including hospice, home health, and physician practice transactions — I can tell you that well-run hospice agencies command some of the highest multiples in all of healthcare. Our database of 78 hospice transactions shows a median EBITDA multiple of 10.8x, with revenue multiples around 1.4x.

Those numbers aren't a typo. Hospice agencies trade at premiums because they combine three things institutional buyers love: recurring revenue from Medicare per diem payments, high EBITDA margins (15-25%), and a demographic tailwind that isn't going away. The aging population guarantees growing demand for decades. But not all hospice agencies are created equal, and the difference between a 6x exit and a 12x exit comes down to a handful of factors I'll walk through here.

How Hospice Revenue Works (And Why It Matters for Valuation)

Unlike most healthcare businesses, hospice revenue is remarkably predictable. Medicare pays a per diem rate for each patient on census, regardless of services provided on any given day. In 2026, the base per diem rates range from approximately $210 for routine home care (the vast majority of days) to $1,100+ for continuous home care and general inpatient care.

This per diem structure creates what is effectively recurring revenue. Every patient on your census generates daily revenue until they either pass away or are discharged. The median length of stay in hospice is approximately 18-25 days, but averages are pulled higher (70-90 days) by long-stay patients. This predictability is what makes hospice so attractive to financial buyers.

Medicare accounts for roughly 85-90% of hospice revenue nationally. Medicaid and private insurance cover the remainder. This heavy Medicare dependence is a double-edged sword: it provides stable reimbursement, but it also means your revenue is subject to CMS policy changes, rate updates, and regulatory scrutiny.

Census: The Metric That Drives Everything

Average daily census (ADC) is to hospice valuation what same-store sales are to retail. It's the number buyers look at first, and it's the metric that most directly correlates with enterprise value. Here's how I see the market stratify based on our transaction data:

• ADC under 50: Small agency. Typically valued at 0.8-1.0x revenue or 6-8x EBITDA. Limited buyer pool, mostly regional operators and smaller PE-backed platforms looking for tuck-ins.
• ADC 50-150: Mid-size agency. This is the most active transaction range. Valued at 1.0-1.5x revenue or 8-11x EBITDA. Attracts both regional and national buyers.
• ADC 150-500: Large agency. Premium valuations of 1.3-2.0x revenue or 10-14x EBITDA. Attracts the major platforms and strategic buyers.
• ADC 500+: Platform-scale. These are the acquisitions that make headlines — Amedisys, VITAS, Kindred at Home. Enterprise values in the hundreds of millions with EBITDA multiples of 12-16x.

But raw census isn't the whole story. I always dig into census trends. A hospice with an ADC of 100 that has been growing 10% annually is worth meaningfully more than one with an ADC of 120 that has been flat or declining. Declining census raises immediate questions about referral source relationships, community reputation, and whether the agency is losing ground to competitors.

What Drives Hospice Multiples Higher

Quality Measures and Star Ratings

CMS publishes Hospice Compare quality data, including star ratings based on the Hospice CAHPS (Consumer Assessment of Healthcare Providers and Systems) survey. These ratings are increasingly tied to reimbursement through the Hospice Quality Reporting Program, and buyers scrutinize them carefully.

A 4-5 star agency signals strong clinical operations, patient satisfaction, and regulatory compliance. In my experience, agencies with consistently high quality scores trade at a 1-2x EBITDA premium over comparable agencies with mediocre ratings. Conversely, agencies with quality deficiencies or recent survey issues face significant buyer skepticism.

Certificate of Need (CON) Protection

Approximately 35 states require a Certificate of Need to operate a hospice agency. In states with stringent CON requirements — like Alabama, Georgia, Tennessee, and South Carolina — the CON itself can represent significant standalone value. It creates a barrier to entry that limits competition and protects your market share.

I've seen agencies in strong CON states trade at premiums of 15-25% over comparable agencies in non-CON states. Buyers are essentially paying for the regulatory moat. If you operate in a CON state, understand that your license is one of your most valuable assets, and the transferability of that CON is a key deal term.

Diversified Referral Sources

Referral source concentration is to hospice what customer concentration is to other businesses. If 40%+ of your admissions come from a single hospital system, SNF chain, or physician group, you have a vulnerability that buyers will price in. That referral source could switch to a competitor, get acquired by an entity with its own hospice program, or simply have a leadership change that disrupts the relationship.

The agencies I've seen command the highest multiples have referral relationships spread across 10+ sources, with no single source exceeding 15-20% of admissions. They also have robust community education and outreach programs that continuously develop new referral relationships.

The Regulatory Landscape: Risks Buyers Assess

Hospice operates under intense regulatory scrutiny, and for good reason — the sector has faced significant fraud investigations and enforcement actions. Buyers conduct extensive compliance due diligence, and regulatory issues can kill deals outright or result in steep valuation discounts.

OIG scrutiny of long lengths of stay. The Office of Inspector General has repeatedly flagged hospices with unusually long average lengths of stay as potential fraud indicators. If your average length of stay significantly exceeds the national median, expect buyers to request a detailed clinical review of long-stay patients. Agencies with average LOS above 120 days face intense scrutiny.

Hospice election and eligibility compliance. Every patient must be certified as having a life expectancy of six months or less by two physicians. Face-to-face encounter requirements at recertification are a common compliance pitfall. Agencies with lax documentation practices carry significant risk of False Claims Act liability, which is a deal-killer for institutional buyers.

State survey deficiencies. Recent condition-level deficiencies on state surveys will either kill a deal or result in a substantial escrow/holdback. Buyers typically want 2-3 clean surveys before they'll pay full price. If you have deficiencies, remediate them and build a track record of compliance before going to market.

PE Activity and the Major Acquirers

Private equity has been aggressively consolidating the hospice industry. The major transactions over the past several years tell the story: UnitedHealth/Optum's $5.4B acquisition of Amedisys, the Kindred at Home portfolio trades, and numerous mid-market platform builds. This is directly relevant to valuation because PE activity creates competitive tension in processes and supports premium multiples.

The most active buyer categories I see in hospice M&A today are:

• PE-backed hospice platforms looking for tuck-in acquisitions in their existing markets or geographic expansion into new states.
• National hospice/home health operators (VITAS, AccordantHealth, Enhabit) pursuing scale and density.
• Health system-affiliated hospice programs looking to build or expand their post-acute continuum.
• Managed care organizations acquiring hospice to control end-of-life costs and improve quality metrics.

Having multiple interested buyer types is exactly what drives competitive processes and premium multiples. If your agency is in a desirable market with a clean compliance record, you likely have more potential buyers than you realize.

Size Matters: The Small Agency Discount

Our transaction data shows a stark size premium in hospice. Agencies under $5M in revenue trade at approximately 6.65x EBITDA and 0.8x revenue. Agencies in the $5-25M range trade at 8.95x EBITDA and 1.25x revenue. Larger agencies trade higher still. The gap is substantial and reflects several realities.

Small agencies often have thin management teams (sometimes just the owner), limited geographic coverage, and higher per-patient overhead. They're also harder to finance — SBA loans for healthcare acquisitions face additional scrutiny, and many lenders are uncomfortable with the regulatory complexity.

If you run a smaller hospice agency and want to maximize your exit, consider whether growth to the $5M+ revenue threshold is achievable within your timeline. The multiple expansion alone — from roughly 6.65x to 8.95x EBITDA — can add millions to your enterprise value. Opening a second location, expanding into adjacent counties, or adding a home health service line are common paths to scaling.

Preparing for a Hospice Exit

Based on my experience advising on hospice transactions, here are the highest-impact actions you can take 18-24 months before going to market:

Invest in compliance infrastructure. Hire or retain a compliance officer, implement a formal compliance program, conduct internal audits, and ensure your clinical documentation is bulletproof. Nothing kills hospice deals faster than compliance concerns.

Grow and diversify census. Add community liaisons, develop new referral relationships, and focus on underpenetrated referral sources. Growing census 15-20% over the pre-sale period meaningfully increases both your revenue base and your attractiveness to buyers.

Build a management team. If you're the sole decision-maker, start delegating. A DON, an administrator, and a community education director who can operate without you removes the key-person risk that depresses multiples.

Document your quality metrics. Compile a quality scorecard showing CAHPS scores, survey results, clinical outcomes, and patient satisfaction trends over 3+ years. Buyers want to see sustained quality, not a single good quarter.

The Bottom Line

Hospice is a premium healthcare asset class for good reason: recurring Medicare revenue, high margins, and unstoppable demographic demand. The agencies that command the highest multiples combine growing census, clean compliance records, diversified referral sources, and strong quality metrics. With PE continuing to aggressively consolidate the space, well-prepared sellers are in a strong position — but the gap between a mediocre exit and a premium exit comes down to preparation, compliance, and understanding what institutional buyers actually value.